Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 1
Submit an article Journal homepage
215
Views
2
CrossRef citations to date
0
Altmetric
Letters to the Editor

Well-differentiated systemic mastocytosis with associated myeloid sarcoma and myelodysplastic syndrome: Diagnostic challenges of an underrecognized entity

Siba El Husseina Department of Pathology, The University of Rochester Medical Center, Rochester, NY, USA;b Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-1338-7107
ORCID Icon,
Shimin Hub Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Hong Fangb Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Sofia Garcesb Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Tariq Muzzafarb Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Sa A. Wangb Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
L. Jeffrey Medeirosb Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
,
Carlos Bueso-Ramosb Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
&
Fatima Zahra Jelloulb Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
 show all
Pages 235-238 | Received 06 Jul 2021, Accepted 30 Aug 2021, Published online: 11 Sep 2021

References

  • Huang L, Wang SA, Konoplev S, et al. Kanagal-Shamanna R: well-differentiated systemic mastocytosis showed excellent clinical response to imatinib in the absence of known molecular genetic abnormalities: a case report. Medicine. 2016;95(41):e4934.
  • Chan EC, Bai Y, Kirshenbaum AS, et al. Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. J Allergy Clin Immunol. 2014;134(1):178–187.
  • Akin CF, Yavuz A, Lipsky PE, et al. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood. 2004;103(8):3222–3225.
  • Akin CE, Nuñez R, Garcia-Montero A, et al. Well-differentiated systemic mastocytosis: a new disease variant with mature mast cell phenotype and lack of codon 816 c-Kit mutations. J Allergy Clin Immunol. 2004;113(2):S327.
  • Álvarez-Twose I, González P, Morgado JM, et al. Complete response after imatinib mesylate therapy in a patient with Well-Differentiated systemic mastocytosis. J Clin Oncol. 2012;30(12):e126–e9.
  • Zhao DD, Zhang L, Li WQ, et al. Well-differentiated systemic mastocytosis with KIT K509I mutation and uterus infiltration in an asian woman with good response to imatinib. Chin Med J. 2019;132(16):2002–2003.
  • Morgado JM, Perbellini O, Johnson RC, et al. CD30 expression by bone marrow mast cells from different diagnostic variants of systemic mastocytosis. Histopathology. 2013;63(6):780–787.
  • Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC, et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol. 2011;24(9):1157–1168.
  • de Melo Campos P, Machado-Neto JA, Scopim-Ribeiro R, et al. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. Leuk Res. 2014;38(10):1245–1251.
  • Zhang LY, Smith ML, Schultheis B, et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res. 2006;30(4):373–378.
  • Tzankov AD, Craig FE, Kelemen K, et al. Mastocytosis: Lessons learned from the 2019 society for hematopathology/european association for haematopathology workshop. Am J Clin Pathol. 2021;155(2):239–266.
  • Sanz-De Pedro M, Wang W, Kanagal-Shamanna R, et al. Myelodysplastic syndromes: laboratory workup in the context of new concepts and classification criteria. Curr Hematol Malig Rep. 2018;13(6):467–476.
  • Alvarez-Twose I, Jara-Acevedo M, Morgado JM, et al. Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis. J Allergy Clin Immunol. 2016;137(1):168–178 e1.
  • Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2530–2541.
  • Chandesris MO, Damaj G, Canioni D, et al.; CEREMAST Study Group. Midostaurin in advanced systemic mastocytosis. N Engl J Med. 2016;374(26):2605–2607., Damaj G, Canioni D.
  • DeAngelo DJ, George TI, Linder A, et al. Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial. Leukemia. 2018;32(2):470–478.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.